| Dr Jintanat Ananworanich
Dr. Jintanat Ananworanich is Associate Director of Therapeutics Research at the U.S. Military HIV Research Program in Maryland, USA, and co-Director of the SEARCH unit at the Thai Red Cross AIDS Research Centre in Bangkok, Thailand. She is Professor of Internal Medicine at the University of Amsterdam and Professor of Pediatrics at the University of Maryland School of Medicine.
Her research interest is in acute HIV infection and HIV cure in children and adults. She leads the RV254/SEARCH010 study in Bangkok that identifies and treats people in acute infection. She is protocol chair of several studies evaluating immune strategies towards a drug-free HIV remission in early treated people. Dr. Ananworanich is also leading an early treated pediatric cohort in Thailand for which immune interventions will be investigated.
| Dr Roy Gulick
Dr. Gulick is Rochelle Belfer Professor in Medicine and Chief of the Division of Infectious Diseases at Weill Cornell Medicine, and Attending Physician at the New York Presbyterian Hospital in New York City. Dr. Gulick’s research interests include designing, conducting and analyzing clinical trials to refine antiretroviral therapy strategies for HIV treatment and prevention and assess antiretroviral agents with new mechanisms of action. He currently serves as Principal Investigator of the Cornell-New Jersey HIV Clinical Trials Unit of the AIDS Clinical Trials Group (ACTG) and the HIV Prevention Trials Network (HPTN), sponsored by the U.S. National Institutes of Health. He also serves as the Co-Chair of the U.S. Department of Health and Human Services (DHHS) Panel on Clinical Practices for Treatment of HIV Infection, a Member of the NIH Office of AIDS Research Advisory Committee (OARAC), a Board Member of the International Antiviral Society-USA. He has presented at national and international meetings and published widely.
| Dr Barbara Shacklett
Dr Barbara Shacklett, PhD, is Professor of Microbiology and Immunology at the University of California, Davis. Her laboratory is recognized for developing and applying innovative approaches to study mucosal immunity to HIV. Over the past 10 years, her work has helped elucidate the relationship between mucosal T-cell responses and immune control of HIV infection, both in human cohorts and in the nonhuman primate model (SIVmac). This work has included studies of HIV “Elite” Controllers, the role of mucosal regulatory T-cells (Treg), mucosal immune reconstitution in individuals on combination antiretroviral therapy (cART), and mucosa-associated invariant T-cells (MAIT cells). Her group also studies the female reproductive tract, including hormonal regulation of innate and adaptive immune responses and the impact of menstrual cycle phases on host defense. She has coauthored over 80 peer-reviewed publications, served on grant review panels in the US, France, and Canada, and is currently an Associate Editor of Mucosal Immunology.
| Prof David O'Connor
Dave O'Connor is a UW Medical Foundation Professor of Pathology and Laboratory Medicine at the University of Wisconsin-Madison. His laboratory studies the interplay of RNA virus pathogenesis, cellular immunity, and host genomics. He is currently a Miegunyah Distinguished Visiting Fellow at the University of Melbourne, where he is on sabbatical at the Peter Doherty Institute for Infection and Immunity along with his wife and colleague Prof. Shelby O'Connor and their 10 year old son Eli.
| A/Prof Stefan Baral
Stefan Baral is an Associate Professor in the Department of Epidemiology at the Johns Hopkins School of Public Health. Stefan completed his training at the University of Toronto in Community Medicine as a Fellow of the Royal College of Physicians and Family Medicine with the Canadian Council of Family Physicians and provides clinical care through the Inner-City Health Associates.
Stefan acts as the director of the Key Population Program within the Center for Public Health and Human Rights. Through this position, Stefan has been supported HIV epidemiology, prevention, and implementation research focused on the epidemiology, human rights contexts, and effective interventions for gay men, bisexual and other cisgender men who have sex with men, transgender women, and sex workers across Western and Central, and Southern Africa and parts of Asia. Stefan has also focused on characterizing optimal metrics for measuring stigma for key populations, evidence-based interventions, and characterizing the causal pathways by which stigma
| Dr Chris Lemoh
Chris Lemoh is an infectious diseases and general physician at Monash Health and Senior Lecturer at Monash University School of Clinical Sciences. He graduated from the University of Tasmania in 1994 with a Bachelor of Medical Sciences, Bachelor of Medicine and Bachelor of Surgery. He holds a Diploma in Clinical Epidemiology from Monash University and is a Fellow of the Royal Australasian College of Physicians. He was awarded a PhD in Medicine from The University of Melbourne in 2014 for research on HIV in Victoria’s African communities. Chris is a former member of the Board of the Australian Federation of AIDS Organisations and current President of the Victorian African Health Action Network. His interests include: refugee health; prosthetic joint infections; sexual and reproductive health; HIV in mobile and marginalised populations and social epidemiology. He is also ranked 1st dan in traditional aikido, Instructor in capoeira and practises jujitsu and kali.
| Prof Rebecca Guy
Professor Rebecca Guy holds a PhD in epidemiology, and a Masters of Applied Epidemiology. She has worked at the Sexual Health Program at Kirby Institute, UNSW, since 2008, and in 2015 was appointed Head of the Surveillance, Evaluation & Research Program. Her research focuses on the epidemiology and prevention of sexually transmissible infections. She has led a large number of collaborative studies, particularly in the area of clinical and public health interventions, which include: large-scale epidemiological studies involving complex surveillance systems; the evaluation of STI control strategies; and rapid point-of-care tests for STIs in remote and developing country settings.